Aurobindo Pharma (AUROPHARMA) Q4 24/25 earnings summary

Executive summary

• Achieved record revenues and EBITDA for FY25, with consolidated revenue at ₹317,237.3 million, driven by strong growth across all business segments, especially in regulated markets and the US, supported by new launches and stable pricing.

• Net profit after tax for FY25 was ₹34,835.7 million, with Q4 net profit at ₹903 crore, reflecting sequential and year-over-year growth.

• Gross margins improved due to favorable product mix, lower raw material costs, and operational efficiencies, despite one-time expenses and negative contributions from certain facilities.

• Net cash position improved significantly, moving from net debt to net cash surplus by year-end, with cash and cash equivalents at ₹55,637.9 million.

• The Board approved and completed a buyback of 5.1 million shares for ₹9,302.4 million in FY25.

Financial highlights

• FY25 revenue: INR 31,724 crore (up 9% YoY); Q4 revenue: INR 8,382 crore (up 11% YoY, 5% QoQ).

• FY25 EBITDA: INR 6,605 crore (margin 20.8%); Q4 EBITDA: INR 1,792 crore (margin 21.4%).

• Q4 net profit: INR 903 crore (up 7% QoQ); FY25 net profit after tax: ₹34,835.7 million.

• Gross margin for FY25: 58.9% (up 214 bps YoY); Q4 gross margin: 59.1% (up 65 bps QoQ).

• Cash and cash equivalents at year-end were ₹55,637.9 million, up from ₹33,854.3 million in FY24.

Outlook and guidance

• Targeting high single-digit revenue growth (excluding transient products) for FY26, with EBITDA margins expected to be maintained at current levels.

• First supplies of four biosimilars to EU markets expected by Q3/Q4 FY26, with multiple regulatory submissions planned, including the first US FDA submission.

• Growth momentum in Europe and key markets expected to continue; clarity on tariffs anticipated in July 2025.

• Statutory auditors issued an unmodified opinion on the FY25 consolidated results and limited review for Q4 FY25.